diabetes

Consuming certain mixtures of common food additives is linked to a slightly increased risk of developing type 2 diabetes, according to an analysis of data from more than 108,000 adults in France. The study, published in PLoS Medicine, identified five mixtures of additives frequently used in ultra-processed foods and concluded that two of them are associated with the disease: the first mixture consisted mainly of emulsifiers, preservatives and a colouring agent, and the second of acidifiers, acidity regulators, colouring agents, artificial sweeteners and emulsifiers.

A review of 202 studies involving more than 56 million mother-child pairs has observed an association between maternal diabetes — including pre-pregnancy and gestational diabetes — and an increased risk of neurodevelopmental disorders in children, such as autism spectrum disorders, attention deficit hyperactivity disorder or intellectual disability. The authors, who publish the results in the journal The Lancet Diabetes & Endocrinology, call for a cautious interpretation of the association, as there is currently little evidence of a causal relationship.

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and obesity, may be associated with a wide range of health effects, both positive - such as a reduced risk of cardiometabolic disorders - and negative - an increased risk of gastrointestinal conditions or hypertension. These are the conclusions of an observational study published in Nature Medicine. The findings are based on analysis of data from 2.4 million participants.

Eating five servings of dark chocolate a week is associated with a reduced risk of type 2 diabetes, according to a long-term US study published today in The BMJ. The research did not find this association with milk chocolate.

The restriction of sugar during the first 1,000 days of life, starting from gestation, may protect against diabetes and hypertension in adulthood, according to a study published in Science. The research uses data from sugar rationing implemented in the United Kingdom after World War II. The findings highlight the long-term benefits of reduced sugar intake during early development.

A team of researchers has analysed the evolution of 4,550 people aged 25 to 65 diagnosed with type 2 diabetes who had been studied for 30 years in the UK. They found that those diagnosed before the age of 40 had a risk of dying almost four times higher than in the general population. If diagnosed later, the risk was 1.5 times higher. The authors publish their findings in the journal The Lancet Diabetes & Endocrinology.

A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.

The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.

In research using a WHO database of adverse drug reactions, the authors identified a signal of disproportionality of suicidal ideation with semaglutide, one of the drugs used to treat type 2 diabetes and obesity. The study, published in JAMA Network Open, did not find this signal for liraglutide, another drug indicated for these treatments.

A paper published today in the journal Science explores the potential of glucagon-like peptide-1 (GLP-1)-based drugs such as semaglutide to treat diseases beyond diabetes and obesity. For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease.